Physicochemical properties of lipid nanoparticles: Effect of lipid and surfactant composition

Drug Development and Industrial Pharmacy

Volumn 37, Issue 7, 2011, Pages 815-824

  Martins, S ^a,b   Tho, I ^b   Ferreira, D C ^a   Souto, E B ^c,d   Brandl, M ^b,e  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^d UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cutina (CP); differential scanning calorimetry (DSC); Dynasan 114 (D14) and 116 (D16); optical single particle sizing (OSPS); photon correlation spectroscopy (PCS); poloxamers; polysorbates; Precirol ATO5 (POL5); witepsol E85 (WE85)

Indexed keywords

DYNASAN 114; DYNASAN 116; GLYCEROL PALMITOSTEARATE; HYDROGENATED CASTOR OIL; LIPID; PALMITIC ACID DERIVATIVE; POLOXAMER; POLYSORBATE 20; POLYSORBATE 40; POLYSORBATE 60; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; SURFACTANT; UNCLASSIFIED DRUG; WITEPSOL E 85;

ARTICLE; CHEMICAL COMPOSITION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; OPTICAL SINGLE PARTICLE SIZING; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; ROOM TEMPERATURE; TECHNIQUE; ZETA POTENTIAL;

CALORIMETRY, DIFFERENTIAL SCANNING; COLLOIDS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; LIPIDS; NANOPARTICLES; PARTICLE SIZE; PHYSICOCHEMICAL PHENOMENA; SURFACE-ACTIVE AGENTS;

EID: 79958735219     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.545414     Document Type: Article

References (38)

1. Constantinides PP, Chaubal MV, Shorr R. (2008). Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Deliv Rev, 60:757-767
2. Joshi MD, Mler RH. (2009). Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm, 71:161-172
3. Mler RH, Souto EB, Gpert T, Gohla S. (2005). Production of biofunctionalized solid lipid nanoparticles for site-specific drug delivery. In: Kumar CSSR (ed.), Biological and Pharmaceutical Nanomaterials (Nanotecnologies for the Life Sciences). Wiley- VCH, pp. 291-307
4. Wissing SA, Kayser O, Mler RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56:1257-1272 (Pubitemid 38510473)
5. Singla AK, Garg A, Aggarwal D. (2002). Paclitaxel and its formulations. Int J Pharm, 235:179-192 (Pubitemid 34185449)
6. Patravale VB, Ambarkhane AV. (2003). Study of solid lipid nanoparticles with respect to particle size distribution and drug loading. Pharmazie, 58:392-395 (Pubitemid 36733847)
7. DiNunzio JC, Williams RO 3rd. (2008). CNS disorders-current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm, 34:1141-1167
8. Gpert TM, Mler RH. (2005). Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target, 13:179-187
9. Werle M. (2008). Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res, 25:500-511
10. Mler RH, Mer K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm, 50:161-177 (Pubitemid 30326695)
11. Lockman PR, Mumper RJ, Khan MA, Allen DD. (2002). Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28:1-13 (Pubitemid 34279373)
12. Kerwin BA. (2008). Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. j Pharm Sci, 97:2924-2935
13. Brandl M, Bachmann D, Drechsler M, Bauer KH. (1990). Liposome Preparation by a new High Pressure Homogenizer Gaulin Micron Lab 40. Drug Dev Ind Pharm, 16,2167-2191 (Pubitemid 20303064)
14. Muchow M, Maincent P, Muller RH. (2008). Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm, 34:1394-1405
15. Rosenblatt KM, Bunjes H. (2009). Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the modification. Mol Pharm, 6,105-120
16. Helgason T, Awad TS, Kristbergsson K, McClements DJ, Weiss J. (2009). Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci, 334:75-81
17. Liu CH, Wu CT, Fang JY. (2010). Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery. Drug Dev Ind Pharm, 36:751-761
18. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. (2008). Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm, 70:75-84
19. Petri B, Bootz A, Khalansky A, Hekmatara T, Mler R, Uhl R et al. (2007). Chemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release, 117:51-58 (Pubitemid 46164866)
20. Batrakova EV, Kabanov AV. (2008). Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release, 130:98-106
21. Freitas C, Mler RH. (1999). Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm, 47:125-132 (Pubitemid 29185115)
22. Driscoll DF. (2006). Lipid injectable emulsions: Pharmacopeial and safety issues. Pharm Res, 23:1959-1969
23. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B et al. (2008). Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev, 60:939-954
24. Frantzen CB, Ingebrigtsen L, Skar M, Brandl M. (2003). Assessing the accuracy of routine photon correlation spectroscopy analysis of heterogeneous size distributions. AAPS Pharmscitech, 4:E36
25. Driscoll D. (2002). The significance of particle/globule-sizing measurements in the safe use of intravenous lipid emulsions. J Dispers Sci Technol, 23,679
26. Liu L, Guo K, Lu J, Venkatraman SS, Luo D, Ng KC et al. (2008). Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials, 29:1509-1517
27. Jenning V, Gohla S. (2000). Comparison of wax and glyceride solid lipid nanoparticles (SLN). Int J Pharm, 196:219-222 (Pubitemid 30105747)
28. Mler RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3-19 (Pubitemid 32209229)
29. Lockman PR, Koziara JM, Mumper RJ, Allen DD. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target, 12:635-641 (Pubitemid 40100711)
30. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. (2008). Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res, 25:2262-2271
31. Bunjes H, Unruh T. (2007). Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev, 59:379-402 (Pubitemid 47259221)
32. Schubert MA, Mler-Goymann CC. (2005). Characterization of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm, 61:77-86 (Pubitemid 41096691)
33. Bunjes H, Drechsler M, Koch MH, Westesen K. (2001). Incorporation of the model drug ubidecarenone into solid lipid nanoparticles. Pharm Res, 18:287-293 (Pubitemid 32595815)
34. Bunjes H, Koch MH, Westesen K. (2003). Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci, 92:1509-1520 (Pubitemid 36792763)
35. Bunjes H, Koch MHJ, Westesen K. (2000). Effect of particle size on colloidal solid triglycerides. Langmuir, 16,5234-5241
36. Kuntsche J, Bunjes H. (2007). Influence of preparation conditions and heat treatment on the properties of supercooled smectic cholesteryl myristate nanoparticles. Eur J Pharm Biopharm, 67:612-620 (Pubitemid 47576621)
37. Bunjes H, Siekmann B, Westesen K. (1998). Emulsions of supercooled melts - a novel drug delivery system. In: Benita, ed. Submicron Emulsions in Drug Targeting and Delivery. Amsterdam: Harwood Academic Publishers, 175-218
38. Kuntsche J, Westesen K, Drechsler M, Koch MH, Bunjes H. (2004). Supercooled smectic nanoparticles: a potential novel carrier system for poorly water soluble drugs. Pharm Res, 21:1834-1843 (Pubitemid 39390096)